SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...

One-year results from the CLASP IID trial and registry showed outstanding results in patients with significant symptomatic degenerative mitral regurgitation (DMR) for Pascal, Edwards Lifesciences Corp ...

One of the biggest stories coming out of Transcatheter Cardiovascular Therapeutics’ annual meeting in Boston this weekend focuses on the success of Edwards Lifesciences Corp.’s freshly FDA-approved ...

BOSTON, Sept. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary ...

Edwards Lifesciences can say two things about its Pascal Precision Valve Repair System. The first is that the technology has FDA approval and the second is that in a study, the device showed its ...

Edwards Lifesciences gains attention after fresh valve data as structural heart devices, valuation debate, and healthcare ...

Please provide your email address to receive an email when new articles are posted on . Patients with severe degenerative mitral regurgitation saw sustained benefits with a novel transcatheter edge-to ...

The Centers for Medicare & Medicaid Services have finalized a new National Coverage Determination for tricuspid transcatheter edge-to-edge repair (T-TEER) in patients suffering from symptomatic ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — A novel mitral valve transcatheter edge-to-edge repair system was noninferior to an existing system in ...